Scalper1 News
Soon-to-be-acquired medical-device giant Covidien (COV) beat analysts’ fiscal Q1 estimates Thursday, sending the stock up modestly. For the quarter ended Dec. 26, profit rose 11% over the year-earlier quarter to $1.11 a share, excluding one-time items. It beat analysts’ consensus by 6 cents, according to Thomson Reuters. Sales rose 2% to $2.69 billion, about $30 million below estimates. Adjusting for foreign-exchange (FX) headwinds, sales rose 6%. Scalper1 News
Scalper1 News